Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 September 2020Website:
http://bioviepharma.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 11 min agoDividend
Analysts recommendations
Institutional Ownership
BIVI Latest News
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET).
ORLANDO, FL / ACCESSWIRE / June 21, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Mobilicom Ltd. (Nasdaq:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 22, at 7 p.m.
Additional presentation will further characterize the potential impact of bezisterim on motor and specific non-motor symptoms of Parkinson's disease Additional presentation will further characterize the potential impact of bezisterim on motor and specific non-motor symptoms of Parkinson's disease
Full Dataset from Phase 2a trial in Parkinson's Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worsened
BioVie Inc, a company in the clinical stage that specializes in innovative drug treatments, has received approval for a clinical trial grant worth up to $13.1 million from the U.S. Department of Defense (DOD) to study Bezisterim (NE3107) for the treatment of neurological symptoms linked to long COVID.
BioVie Inc (NASDAQ:BIVI) revealed data at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit in Boston showing that its main drug NE3107 could potentially rebalance certain genes linked to dementia, metabolism, and inflammation. The company also announced that bezisterim has been approved as the generic name for NE3107 by both the United States Adopted Names Council and the World Health Organization International Nonproprietary Names expert committee.
BioVie Inc. (BIVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
BioVie Inc (NASDAQ:BIVI) told investors it has secured sufficient funds through a recently completed financing to progress its near-term clinical priority, developing its lead asset NE3107 for Parkinson's disease. It increased its cash balance by approximately $18.8 million after closing an equity financing round last week for gross proceeds of $21 million.
BioVie (NASDAQ: BIVI ) stock is rocketing higher on Friday announed positive data from two clinical trials of NE3107. NE3107 is BioVie's inhibitor of inflammatory activation of ERK and NFkB.
BioVie Inc (NASDAQ:BIVI) shares surged 130% in early trade on Friday after the company revealed that its lead asset NE3107 has demonstrated the potential to improve motor and non-motor symptoms in patients with Parkinson's disease in a mid-stage clinical trial. The company said data from its Phase 2a trial showed Parkinson's Disease patients treated with NE3107 experienced significant improvements in non-motor symptoms and motor control, while patients in the placebo arm worsened.
- 1(current)
- 2
What type of business is BioVie?
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
What sector is BioVie in?
BioVie is in the Healthcare sector
What industry is BioVie in?
BioVie is in the Biotechnology industry
What country is BioVie from?
BioVie is headquartered in United States
When did BioVie go public?
BioVie initial public offering (IPO) was on 18 September 2020
What is BioVie website?
https://bioviepharma.com
Is BioVie in the S&P 500?
No, BioVie is not included in the S&P 500 index
Is BioVie in the NASDAQ 100?
No, BioVie is not included in the NASDAQ 100 index
Is BioVie in the Dow Jones?
No, BioVie is not included in the Dow Jones index
When does BioVie report earnings?
The next expected earnings date for BioVie is 08 November 2024